ClinicalTrials.gg
Not yet recruitingNCT06992726Updated Jun 17, 2025

Improvement of Fish Oil in Obesity With Mild Cognitive Impairment

A Phase 4 interventional study of Fish oil intervention and Placebo intervention in Obesity and Mild Cognitive Impairment, sponsored by Weiwei Ma. Not yet recruiting. Open to participants aged 35 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-06-17.

Sponsored by Weiwei Ma · Phase 4, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
35 Years to 80 Years
Sex
All
01

Study summary

Eighty-eight patients with obesity with mild cognitive impairment(MCI) from the Multicenter Nutrition and Chronic Disease Cohort, who met the inclusion and exclusion criteria, were selected as study subjects and randomly divided into 2 groups, i.e., the placebo group and the n-3 PUFA intervention group. Subjects in the intervention group were given supplemental n-3 PUFA (supplied in 1.36 g fish oil capsules); the placebo group took placebo (1.36 g/d), and the intervention period was 12 consecutive months. General information, dietary intake, body composition, exercise, overall cognitive function and multidimensional cognitive function, abundance of Mycobacterium avium and its metabolites acetic acid and propionic acid content, beige adiposity markers, inflammation-related factors, and lipid metabolism were collected at baseline, at the end of 6 months and at the end of 12 months of the intervention, respectively, and the adherence of the two groups of subjects was also assessed. To analyze the effects of n-3 PUFA intervention on cognitive function in patients with obesity with MCI and to explore the possible mechanisms.

02

Conditions studied

  • Obesity
  • Mild Cognitive Impairment
03

In context

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

This study's planned enrollment of 88 is above the median of 67 across 9,043 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Weiwei Ma is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meet the diagnostic criteria of obesity and MCI;
  • Age between 35 and 80 years old;
  • No dieting or stop dieting in the last 3 months, no fish oil supplements, or willing to stop self-administration of fish oil 3 months before the intervention;
  • Voluntarily participate in the program with , and sign the informed consent form.

Exclusion criteria

Exclusion Criteria:

  • Those with neuropsychiatric disorders such as stroke, epilepsy, or schizophrenia;
  • Those with cognitive impairment caused by depression, thyroid disease, traumatic brain injury, drug or alcohol intoxication;
  • Those with a history of cerebrovascular disease or cognitive impairment caused by severe cardiac, hepatic, pulmonary, or renal impairment;
  • Those who are complete vegetarians and are unable to comply with the balanced dietary pattern;
  • Those who suffer from severe angina pectoris, asthmatic bronchitis, severe infections , systemic lupus erythematosus, malignant tumors, and other diseases that may affect one's dietary habits and life;
  • Coeliac disease with lipid malabsorption.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
88 participants (estimated)

Study arms

  • Placebo comparator
    control group

    Other: Placebo intervention

  • Experimental
    Fish oil intervention group

    Dietary Supplement: Fish oil intervention

Interventions

  • Dietary supplementFish oil intervention

    The diet was based on the principles of a balanced diet, and subjects in this group were additionally supplemented with n-3 PUFA (provided as 1.36 g fish oil capsules), with the rest of the intervention being the same as in the control group.

  • OtherPlacebo intervention

    Diet based on the principles of a balanced diet, taking placebo capsules with the same appearance and odor as the fish oil capsules.

06

What researchers measure

Primary outcomes

  1. Height, Waist

    Measurement of the subject's height and waist circumference using a tape measure.

    Time frame: Baseline, 6 months, 12 months

  2. weight

    The weight of the subjects was measured using a weighing scale.

    Time frame: Baseline, 6 months, 12 months

  3. Total Body Water

    Measuring Total Body Water (L) with the InBody Body Composition Analyzer.

    Time frame: Baseline, 6 months, 12 months

  4. body protein, inorganic salts, and body fat

    Measurement of body protein, inorganic salts, and body fat using the InBody Body Composition Analyzer (kg)

    Time frame: Baseline, 6 months, 12 months

  5. Appendicular skeletal muscle mass index

    Skeletal muscle mass of the extremities is the sum of the muscle mass of both upper and lower extremity skeletal muscles, which was measured using a body composition meter. The appendicular skeletal muscle mass index (ASMI) is the mass of the skeletal muscles of the extremities divided by the square of the height (kg/m2).

    Time frame: Baseline, 6 months, 12 months

  6. Cognitive function assessment

    Cognitive function was assessed using the Montreal Cognitive Assessment (MoCA) scale, which is a 30-point scale that includes multiple dimensions of cognitive functioning, including visuospatial and executive functioning, naming, memory, attention, language, abstraction, delayed recall, and orientation. The MCI diagnostic criteria were: \<6 years of education, MoCA score ≤19; \>7 years of education but ≤12 years, MoCA ≤22; \>12 years of education, MoCA ≤24.

    Time frame: Baseline, 6 months, 12 months

  7. Dietary composition

    The food frequency questionnaire (FFQ) was used for the survey assessment. With reference to the FFQ questionnaire used in the Nutrition and Health Status Survey of Chinese Residents, a total of 72 food inquiry entries in 11 food groups were included, with a focus on n-3 PUFA-rich foods, as well as the intake of edible oils and condiments. Auxiliary survey tools such as the Retrospective Dietary Survey Auxiliary Atlas were used to help respondents recall. The Standardized Version of the Chinese Food Composition Table (6th Edition) was used to calculate the energy and nutrient intake of the population, including the intake of dietary fatty acids.

    Time frame: Baseline

  8. Dietary Inflammation Index

    The dietary inflammatory index (DI) for each dietary component/nutrient was calculated separately for each individual based on the mean and standard deviation of the per capita daily intake of each dietary component or nutrient and the corresponding dietary effect index of each component.If a food increases the level of pro-inflammatory factors or decreases the level of anti-inflammatory factors, it is labeled as "+1" for a pro-inflammatory effect; conversely, it is assigned "-1" for an anti-inflammatory effect. If there was no significant change in inflammatory markers, "0" was assigned as no pro/anti-inflammatory effect. The final DI score for each food was accumulated to obtain an overall dietary DI score for the individual; the higher the total DI score, the greater the pro-inflammatory effect of the diet, and conversely, the greater the anti-inflammatory effect.

    Time frame: Baseline

  9. Species and abundance of intestinal flora

    Detection Methods:Fecal flora was detected by designing and amplifying sequences specific to B. anthropophilus and then applying RT-qPCR.

    Time frame: Baseline, 6 months, 12 months

  10. Metabolite levels of intestinal flora

    HPLC-MS/MS

    Time frame: Baseline, 6 months, 12 months

  11. Plasma inflammatory factor levels

    High-Throughput Liquid Protein Chip

    Time frame: Baseline, 6 months, 12 months

  12. Erythrocyte Membrane n-3 PUFA Levels

    Gas Chromatography

    Time frame: Baseline, 6 months, 12 months

  13. Plasma Beige Lipid Marker Levels

    Double antibody sandwich ELISA

    Time frame: Baseline, 6 months, 12 months

  14. Fecal Akkermansia abundance

    qPCR

    Time frame: Baseline, 6 months, 12 months

  15. Fecal Amuc_1100 expression levels

    Fecal Amuc_1100 mRNA expression was detected using Realtime-PCR.

    Time frame: Baseline, 6 months, 12 months

  16. Detection of signaling pathway related indicators of plasma fat metabolism

    Enzyme colorimetric method

    Time frame: Baseline, 6 months, 12 months

  17. Levels of lipopolysaccharide

    Enzyme colorimetric method

    Time frame: Baseline, 6 months, 12 months

  18. Plasma lipid oxide concentrations

    LC-MS/MS

    Time frame: Baseline, 6 months, 12 months

  19. Levels of fatty acid synthetase

    Enzyme colorimetric method

    Time frame: Baseline, 6 months, 12 months

Secondary outcomes

  1. Blood lipids

    Enzyme colorimetric method

    Time frame: Baseline, 6 months, 12 months

  2. Fasting blood glucose

    Hexokinase method

    Time frame: Baseline, 6 months, 12 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2025; primary completion for Dec 2026, 16 months later.

Of 190 non-industry phase 4 interventional studies under Obesity, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 52. This study's planned 16 months is below that.

Counting every sponsor, half of 210 studies reached it within 31 months; a quarter within 15 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2025
First posted
May 28, 2025
StartEst.
Aug 1, 2025
Primary completionEst.
Dec 1, 2026
CompletionEst.
Jun 30, 2027
Last update
Jun 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06992726
Lead sponsor
Weiwei Ma
Responsible party
Weiwei Ma (professor, Capital Medical University) — Sponsor-investigator
First posted
May 28, 2025
Start date
Aug 1, 2025 (estimated)
Primary completion
Dec 1, 2026 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Jun 17, 2025

Study contacts

Weiwei Ma
Contact
weiweima@ccmu.edu.cn
+8615810307505
Ruiqi Mu
principal investigator · Capital Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion